PhaseV

Development and medical teams in Tel Aviv

PhaseV was founded in 2023 by Raviv Pryluk, Elad Berkman and Dan Goldstaub, according to Finder. A job ad from the company describes a headquarters in Cambridge, Massachusetts, and research and development and medical teams in Tel Aviv. So its Israeli link comes not only from who the founders are, but also from where the product is built. The company serves pharmaceutical companies, biotechnology companies and organizations that run trials for them. It develops software for the clinical development process: from questions about choosing patients and designing the protocol, to choosing trial sites and running the trial.

Different responses within the same study group

Part of the product analyzes variation in how patients respond to treatment. According to the company's website, the models examine biological signals and multivariable clinical data to identify subgroups and markers. The company also uses causal learning and graphs that describe relationships between factors linked to disease progression and outcomes. The aim is to understand which differences in the population matter for the design, and not to settle for the average outcome of all participants. The output is shown to development teams who need to decide which populations to test, what to measure and how to define the next study.

Simulating adaptive design

The company's trial design tool lets users test different statistical designs in simulation. The website describes comparing Bayesian design and adaptive trials, in which decisions during the study rely on information that accumulates according to set rules. Other tools are meant for choosing trial sites and analyzing their performance. The description of the medical role at the company includes clinical oversight of the models and interpretation of their results. So the product is described as software for a multidisciplinary team of researchers, doctors and data people. It is not a system that decides on its own to change the treatment of each trial participant. The simulations are used to compare design options before the trial plan is chosen. Medical oversight and clinical interpretation are mentioned explicitly in the role of the medical team.

Funding and reported commercial activity

On 13 May 2025, CTech reported a $50 million Series A led by Accel and Insight Partners. Viola Ventures, EXOR and LionBird also took part. Published total funding reached $65 million. Earlier, in October 2023, the company raised $15 million led by Viola Ventures and Exor Ventures. The same article said the company had more than 30 customers worldwide, including large pharmaceutical companies, not all of them named. This is a figure the company gave as of the publication date.

An example from insulin research, and how results are presented

The website describes work with Oramed following a trial of insulin taken by mouth. According to the company's description, the analysis identified a subgroup that responded to the treatment, and this was compared with findings from other studies. It is an example of using data from an existing trial to suggest a direction for a new test. The website also shows reductions in trial costs and times based on collaborations the company lists. These figures are attributed to the vendor and are not presented here as a guaranteed result. Identifying a subgroup and publishing a simulation are not, by themselves, proof that the drug works or that a new design has already succeeded in another trial.